TYPTFTRYPTAMINE THERAPEUTICS LTD.

About TRYPTAMINE THERAPEUTICS LTD. (TYPTF)

TRYPTAMINE THERAPEUTICS LTD. (TYPTF) is a Biotechnology company headquartered in Camberwell, VA, Australia whose shares trade over-the-counter on the Pink tier.

Tryptamine Therapeutics Limited is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. Tryptamine Therapeutics intends to accomplish this through the development of an IV infusion of psilocin (the active metabolite of psilocybin) which addresses many of the current limitations associated with orally administered psilocybin used by the majority of competitors in the field. Tryp's lead programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy.

TYPTF key facts

Ticker symbol

TYPTF

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

Camberwell, VA, Australia

Estimated market cap

$2.97M (as of Apr 11, 2025)

Shares outstanding

196,893,706

Reporting standard

International Reporting: ASX - Australian Securities Exchange

Audit status

Audited

Fiscal year end

6/30

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with T